Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.36 HKD | -2.86% | +4.62% | -6.85% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
End-of-day quotes
Sector Biopharmaceuticals
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
181M | - | - | - | |||
89.33B | ||||||
41.19B | ||||||
31.87B | ||||||
24.52B | ||||||
15.68B |